Anti-Human PCSK9 Reference Antibody (B1655, RUO) (HV275186)

Name: Anti-Human PCSK9 Reference Antibody (B1655, RUO)
Brand: abinScience
SKU: HV275186
Price: 370 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	HV275186
Описание	Anti-Human PCSK9 (B1655) (HV275186) is a research-grade recombinant antibody targeting Proprotein convertase subtilisin/kexin type 9. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Реактивность видов	Human
Применения	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	IgG
ID клона	B1655
Цель	EC:3.4.21.-, NARC-1, NARC1, Neural apoptosis-regulated convertase 1, PC9, PCSK9, Proprotein convertase 9, Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9
Уровень эндотоксинов	< 10 EU/mg
Чистота	>95% as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	Q8NBP7
Форма	Liquid
Буфер хранения	0.01M PBS pH 7.4. Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Альтернативные названия	B1655
Фон	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha). 1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658 2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796 3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702 4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458 5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827 6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
Примечание	For research use only. Not suitable for clinical or therapeutic use.